Pain And Function Are Best Endpoints For Knee Cartilage Trials – FDA Panel

Joint pain and function are the most clinically meaningful efficacy outcomes and should both be used as primary endpoints for clinical trials of cellular products for treatment of knee cartilage defects, FDA's Cellular, Tissue and Gene Therapies Advisory Committee recommends